1.To both of them: There have been several large scale trials investigating interventions to prevent type 2 diabetes in IGT populations such as STOP-NIDDM and DREAM. And trials as VALUE， KYOTO Heart， LIFE， showed that RAS inhibitors could reduce the incidence of NOD.  How do you think of the difference between NAVIGATOR and those studies? And what is the significance of these unique features of NAVIGATOR?

    目前已有多项大规模临床研究，探索对IGT患者进行干预以预防新发糖尿病，同时RAS抑制剂在减少NOD方面已经有了很多证据，比如VALUE， KYOTO Heart， LIFE， SCOPE等，NAVIGATOR研究与这些临床试验有什么不同？这些独特之处的重要意义何在？

     2.Why one "antihypertensive" agent was tested in the "diabetes" prevention trial? Any common mechanism between hypertension and diabetes?　How do you think about drug’s  pleiotropic effect  ?

为什么在糖尿病预防试验中选用抗高血压药物？在高血压和糖尿病两种疾病之间有什么共同的发病机制吗？您是怎样看待药物的多效性的？

      3.What do you think is the mechanism for valsartan to reduce the incidence of NOD? Do you think insulin resistance plays a major role in this effect? And what is the role of the AT1 receptor selectivity of valsartan in this effect?

您认为缬沙坦预防糖尿病的作用机制是怎样的？胰岛素抵抗以及缬沙坦作为选择性AT1受体阻断剂，在这种作用机制中起什么作用呢？

     4.Prevention is becoming the key point of disease control. Cardiovascular disease and type 2 diabetes are demonstrated to be preventable. About 10% of IGT cases progress to type 2 diabetes annually and NAVIGATOR study shows that Valsartan can reduce the development of new onset diabetes. Could you please evaluate the significance of this result in terms of diabetes prevention?

    当前疾病控制的重心已开始向预防转移，心血管疾病和糖尿病都是可预防的，IGT向2型糖尿病的转化率约为10%，NAVIGATOR研究证明了代文能减少IGT向2型糖尿病的转化，您能评价一下这个结果对预防糖尿病的意义吗？

    5.IGT has becoming more and more prevalent both in China and in the world. Do you think our clinical doctors pay enough attention on the risk of IGT? What is the impact of NAVIGATOR study on the future clinical practice in the area of intervention of IGT?

    您认为目前临床实践中医生和患者对IGT的危险性是否有足够认识，NAVIGATOR研究结果的公布是否有助于对IGT干预的普及？

     6.As for the non significant difference of CV endpoints between valsartan and placebo， what’s your opinion ? What do you think is the main reason?

关于缬沙坦和安慰剂组的CV终点事件没有显著差异，您是怎么认为的？